Apollomics
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Employees
- 45
- Market Cap
- -
- Introduction
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05367388
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
APL-102 Capsule in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: APL-102 Capsules
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05055518
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05054543
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Zhejiang University, Hangzhou, China
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04839341
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Zhejiang University, Hangzhou, China
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Conditions
- Gastroesophageal Junction AdenocarcinomaNSCLCLung CancerBrain TumorGlioblastoma MultiformeEGFR Gene MutationSolid TumorsAdvanced CancerRenal CancerMET Alteration
- Interventions
- Drug: APL-101 Oral Capsules
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 497
- Registration Number
- NCT03175224
- Locations
- 🇭🇺
Komarom-Esztergom Varmegyei Szent Borbala Korhaz, Tatabanya, Hungary
🇺🇸Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Moffitt, Tampa, Florida, United States